Form 4: Progyny Director Elizabeth Bierbower Granted 44,000 Stock Options

Progyny, Inc. Director Elizabeth D. Bierbower was granted 44,000 stock options with an exercise price of $20.89, vesting over four years.

Summary

• Elizabeth D. Bierbower, a Director of Progyny, Inc. (PGNY), was granted 44,000 stock options on May 22, 2025.
• The stock options have an exercise price of $20.89 per share.
• The options will vest 25% on the first anniversary of the grant date, with the remaining portion vesting in equal quarterly installments through the fourth anniversary of the grant date.
• Vesting is contingent upon Ms. Bierbower's continued service on each applicable vesting date.
• The options have an expiration date of May 21, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options is a routine compensation event for a director, aligning their interests with the company's long-term performance. It is a positive for the director as it represents potential future value, and neutral for the company as it's a standard part of its compensation structure.

Positives

• The grant of stock options aligns the director's financial interests with the long-term performance and shareholder value of Progyny, Inc.
• It represents a standard form of equity compensation for directors, incentivizing their continued commitment and strategic oversight.

Negatives

• The value of the options is entirely dependent on Progyny's stock price appreciating above the $20.89 exercise price.
• There is no immediate cash inflow for the director from this grant.
• The options are subject to a vesting schedule, meaning they are not immediately exercisable and can be forfeited if service ends prematurely.

Risks

• The primary risk is that Progyny's stock price may not exceed the exercise price of $20.89, rendering the options worthless.
• The options are subject to forfeiture if the reporting person's service to the company ceases before the vesting dates.

Future Outlook

The future value of these options is contingent on Progyny's stock performance exceeding the exercise price of $20.89 per share over the next decade, with vesting tied to continued service.

Industry Context

The grant of stock options to directors is a common practice in the healthcare benefits and fertility services industry, aligning director incentives with long-term shareholder value and retention.

Comparison to Industry Standards

• Granting stock options as part of director compensation is a standard practice across publicly traded companies, including those in the healthcare and benefits sector.
• The specific size and exercise price of this grant would typically be benchmarked against peer companies of similar market capitalization and industry focus, though specific comparable grants are not detailed in this filing.

Stakeholder Impact

• Shareholders: Potential future dilution upon exercise of options, but also benefits from the alignment of the director's interests with long-term shareholder value.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• The options will begin vesting on the first anniversary of the grant date (May 22, 2026), with subsequent quarterly vesting through May 22, 2029, subject to continued service.

Key Dates

Keywords

Progyny, PGNY, Stock Option, Form 4, Insider Transaction, Director Compensation, Equity Grant, Vesting